Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (24,235)	$ (1,159)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash component of impairment loss on classification of assets as held for sale	586	0
Loss on disposal of Services Business	73	0
Gain on insurance recovery	0	(165)
Loss on extinguishment of debt	0	1,389
Recovery of bad debt	0	(75)
Depreciation	447	918
Stock-based compensation expense	2,656	837
Amortization of deferred financing costs and debt discount	0	755
Change in fair value of derivative liability	0	(10,080)
Changes in deferred rent	(108)	(97)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	(523)	(252)
Prepaid expenses, other assets, and deferred costs	(855)	(876)
Accounts payable and accrued expenses	(431)	907
Accrued severance and retention cost obligations	2,809	0
Deferred revenue	1,018	147
Net cash used in operating activities	(18,563)	(7,751)
Cash flows from investing activities:
Proceeds from insurance recovery	0	216
Proceeds from sale of Services Business	2,549	0
Purchases of property and equipment	(547)	(632)
Net cash provided by (used in) investing activities	2,002	(416)
Cash flows from financing activities:
Proceeds from public offerings	41,400	62,000
Proceeds from sale of preferred stock	0	544
Repayment of debt	0	(15,000)
Payments of deferred offering costs and underwriting discounts and commissions	(3,422)	(6,875)
Proceeds from employee stock purchase plan issuance	106	68
Proceeds from exercise of stock warrants	0	55
Proceeds from exercise of stock options	0	9
Net cash provided by financing activities	38,084	40,801
Net increase in cash and cash equivalents	21,523	32,634
Cash and cash equivalents, beginning of period	32,243	1,402
Cash and cash equivalents, end of period	53,766	34,036
Supplemental cash flow information:
Cash paid for interest	0	49
Noncash financing and investing activities:
Beneficial conversion feature on sale of Series D-2 preferred stock	0	909
Beneficial conversion feature for antidilution adjustment	0	214
Adjustment of preferred stock to redemption value	0	510
Deferred offering costs included in accounts payable and accrued expenses	52	0
Equipment purchases in accounts payable and accrued expenses	12	11
Impairment of fixed asset	0	51
Deferred offering costs reclassified to additional paid-in capital	3,388	4,127
Warrant derivative liability reclassified to additional paid-in capital	0	2,701
Conversion of convertible preferred stock to common stock	$ 0	$ 88,790